Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$115.62 USD
-0.93 (-0.80%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $115.62 0.00 (0.00%) 7:08 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Sarepta Therapeutics (SRPT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$163.44 | $224.00 | $128.00 | 40.23% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Sarepta Therapeutics comes to $163.44. The forecasts range from a low of $128.00 to a high of $224.00. The average price target represents an increase of 40.23% from the last closing price of $116.55.
Analyst Price Targets (16)
Broker Rating
Sarepta Therapeutics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.48 a month ago based on 21 recommendations.
Of the 20 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70% and 10% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 9.52%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 15 | 15 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.48 | 1.48 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
2/29/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
2/29/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Hold | Hold |
2/20/2024 | Evercore Partners | Gavin Clark-Gartner | Hold | Hold |
2/16/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
2/14/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Strong Buy |
1/31/2024 | BMO Capital Markets | Kostas Biliouris | Not Available | Strong Buy |
11/1/2023 | Not Identified | Not Identified | Hold | Hold |
11/1/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
10/31/2023 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 20 |
Average Target Price | $163.44 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.13 |